Drug Profile


Alternative Names: Lung targeted site specific immunomodulator - Qu Biologics

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Qu Biologics
  • Class Bacterial antigens; Cancer vaccines
  • Mechanism of Action Immunomodulators; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 28 Nov 2017 Pharmacodynamics data from a preclinical trial in Cancer released by Qu Biologics
  • 24 Mar 2017 Phase-IIa development for Non-small cell lung cancer is ongoing in Canada (SC)
  • 01 Nov 2016 Qu Biologics withdraws phase I trial in Non-small cell lung cancer (In volunteers), prior to enrolment, in Canada (NCT02897999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top